Latham & Watkins
Firm overview:
Latham & Watkins has significant trial experience and a winning track record across US and global venues on the most complex patent disputes, often involving technologies developed around the world. Its reputation of success has led clients facing long odds to hand over critical IP cases midway and the firm emphasises its “willingness to go to trial”.
Latham deploys trial counsel experienced in the relevant jurisdiction for patent cases, such as the Eastern District of Texas, the District Courts of California, the International Trade Commission, the Federal Circuit, or numerous global venues.
The firm also regularly achieves successful results in patent mediations, arbitrations, and other forms of alternative dispute resolution as an alternative to protracted litigation.
Team overview:
Significant changes to Latham’s patent team over the past year include the departure of distinguished trial lawyer Doug Lumish, now co-head of Weil’s IP, Technology & Science litigation practice. Lumish left alongside Jeff Homrig and Gabe Gross, who also took expertise in disputes related to patents and other IP to Weil.
Earlier in 2025, a five-partner team from Latham joined Cleary Gottlieb; Clement Naples, Bert Reiser, Giri Pathmanaban, Greg Sobolski, and Thomas Yeh have experience in handling high-profile patent and trade secrets cases.
However, the firm boosted its IP capabilities in August 2025 with the addition of first-chair lawyer Adam Greenfield, who rejoined the firm after a stint at White & Case. Greenfield specialties in patent and trade secret disputes across technology sectors including artificial intelligence, automotive, defence, energy, financial services, manufacturing, and medical devices.
Latham’s existing bench of expertise on patent matters includes DC partner Matthew Moore, who represents leading companies in existential litigation and high-stakes patent disputes, and Michael Morin, global chair of Latham’s IP Litigation Practice, who has led some of the highest-profile patent cases in the US, particularly in life sciences.
Key matters:
- Regeneron v Novartis
In 2025 Latham & Watkins stepped in to represent Novartis in its high-profile patent dispute with Regeneron over blockbuster eye disease drug Eylea, replacing Kirkland & Ellis amid a conflict of interest dispute.
The team’s arrival follows Kirkland’s withdrawal after Regeneron petitioned the US District Court for the Southern District of New York in June 2025 to bar the firm from representing Novartis, citing Kirkland’s prior work on Regeneron’s global IP strategy.
- Protection of AbbVie’s blockbuster immunology drug Rinvoq
A Latham team represented AbbVie in securing the latest of five patent litigation settlements with generic manufacturers, protecting AbbVie’s blockbuster immunology drug Rinvoq until 2037. AbbVie’s stock rose 3% after the announcement in September 2025.
- Nippon Shinyaku v Sarepta Therapeutics et al
Representing Sarepta Therapeutics, the firm successfully defended against a $290 million patent infringement claim and secured a $116 million award for Sarepta in a week-long trial in Delaware.
Clients:
Clients: AbbVie, Regeneron, Sarepta Therapeutics
